AGIANA PHARMACEUTICALS AS: årsregnskap 2022 vs 2021
Slipped into loss
approved 2023-06-08; registry 2023-06-28; journal 2023 531658
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for AGIANA PHARMACEUTICALS AS. Revenue 0 NOK → 0 NOK (0.0%). Net result 0 NOK → -2 958 NOK. Equity 30.0k NOK → -2.93m NOK.
On the constructive side: cash rose. Pressures included: operating result weakened; fell into a net loss; equity eroded.
Also worth watching: thin equity buffer; headcount (årsverk) changed. All figures are taken from the published annual accounts for AGIANA PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Cash rose
Bank deposits 30.0k NOK → 4.00m NOK (+13232.3% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result 0 NOK → -2.85m NOK. Calculated
-
↓
Fell into a net loss
Net result flipped from 0 NOK profit to a loss of 2 958 NOK. Calculated
-
↓
Equity eroded
Book equity 30.0k NOK → -2.93m NOK (equity ratio 100.0% → -69.3%). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -69.3% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Headcount (årsverk) changed
Reported FTEs 0 → 1. Reported fact